State Street’s Sonnet BioTherapeutics SONN Stock Holding History

State Street’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,534	Closed	-$103K	–	4344
2025 Q3	$103K	Buy	+22,534	New	+$99.9K	﹤0.01%	4049
2023 Q3	–	Sell	-537	Closed	-$46.3K	–	4584
2023 Q2	$46.3K	Buy	+537	New	+$37.9K	﹤0.01%	4440
2022 Q3	–	Sell	-53	Closed	-$36K	–	4951
2022 Q2	$36K	Buy	53 +26	+96%	+$18.6K	﹤0.01%	4791
2022 Q1	$25K	Buy	27 +2	+8%	+$1.69K	﹤0.01%	4871
2021 Q4	$26K	Hold	25	–	–	﹤0.01%	4764
2021 Q3	$38K	Hold	25	–	–	﹤0.01%	4658
2021 Q2	$99K	Buy	+25	New	+$109K	﹤0.01%	4367

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

State Street's SONN Position: Q4 2025 in Review

State Street sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 22,534 shares — an estimated $103K sold.

State Street first reported a position in SONN in Q2 2021 and held it in 7 quarters. The position peaked at $103K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

State Street reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
State Street sold 22,534 Sonnet BioTherapeutics shares in Q4 2025, an estimated $103K.
State Street first reported a position in Sonnet BioTherapeutics in Q2 2021 and held it in 7 quarters.
State Street's Sonnet BioTherapeutics position peaked at $103K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on State Street's 13F filing for Q4 2025, filed 13 Feb 2026.